BR0303080A - Seleção de marcadores - Google Patents

Seleção de marcadores

Info

Publication number
BR0303080A
BR0303080A BR0303080-6A BR0303080A BR0303080A BR 0303080 A BR0303080 A BR 0303080A BR 0303080 A BR0303080 A BR 0303080A BR 0303080 A BR0303080 A BR 0303080A
Authority
BR
Brazil
Prior art keywords
parameters
measure
diagnostic
selecting
relationship
Prior art date
Application number
BR0303080-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Tim Jatkoe
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BR0303080A publication Critical patent/BR0303080A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)
BR0303080-6A 2002-03-29 2003-03-28 Seleção de marcadores BR0303080A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36879002P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
BR0303080A true BR0303080A (pt) 2004-02-17

Family

ID=27805329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0303080-6A BR0303080A (pt) 2002-03-29 2003-03-28 Seleção de marcadores

Country Status (10)

Country Link
US (2) US20030194734A1 (enExample)
EP (1) EP1349104A3 (enExample)
JP (1) JP2004163388A (enExample)
KR (1) KR20030078803A (enExample)
CN (1) CN1495272A (enExample)
AR (1) AR039212A1 (enExample)
AU (1) AU2003203529A1 (enExample)
BR (1) BR0303080A (enExample)
CA (1) CA2422309A1 (enExample)
MX (1) MXPA03002865A (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1788083A4 (en) * 2004-08-02 2008-08-13 Banyu Pharma Co Ltd METHOD FOR THE ADOPTION OF MEDICAMENT SENSITIVITY AGAINST THE INHIBITOR CDK4
WO2006060653A2 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
JP2008528024A (ja) * 2005-01-31 2008-07-31 ディジタルジェノミクスインコーポレーション 肺癌診断用マーカー遺伝子
KR100690250B1 (ko) * 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
US20070207467A1 (en) 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
US20080058432A1 (en) * 2006-03-03 2008-03-06 Yixin Wang Molecular assay to predict recurrence of Duke's B colon cancer
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
SG144111A1 (en) * 2006-12-22 2008-07-29 Shares Advisors Llc X Portfolio selection for custom indices of public securities based on state of domicile of issuing company
US20080206777A1 (en) 2007-02-27 2008-08-28 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
US20090192045A1 (en) * 2008-01-22 2009-07-30 Yuqiu Jiang Molecular staging of stage ii and iii colon cancer and prognosis
US20110059464A1 (en) 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US9206482B2 (en) 2009-04-29 2015-12-08 Genomedx Biosciences Inc. Systems and methods for expression-based classification of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000347B (el) * 1988-12-21 1992-06-25 Ortho Diagnostic Systems Inc Μεθοδος παραγωγης νουκλεοτιδικων ανιχνευτων χρησιμοποιωντας ενα συμπληρωμα γεφυρωσεως.
US6350576B1 (en) * 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6882990B1 (en) * 1999-05-01 2005-04-19 Biowulf Technologies, Llc Methods of identifying biological patterns using multiple data sets
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
CA2375943A1 (en) * 1999-07-15 2001-01-25 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof

Also Published As

Publication number Publication date
CA2422309A1 (en) 2003-09-29
EP1349104A3 (en) 2004-01-02
US20030194734A1 (en) 2003-10-16
CN1495272A (zh) 2004-05-12
JP2004163388A (ja) 2004-06-10
US20100009371A1 (en) 2010-01-14
MXPA03002865A (es) 2004-08-11
EP1349104A2 (en) 2003-10-01
AU2003203529A1 (en) 2003-10-23
KR20030078803A (ko) 2003-10-08
AR039212A1 (es) 2005-02-09

Similar Documents

Publication Publication Date Title
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
AR039212A1 (es) Metodos de seleccion de porfolios de marcadores para uso en aplicaciones de diagnostico, maquinas para identificar porfolios de marcadores, articulos que comprenden instrucciones para seleccionar dichos porfolios ,y porfolios de diagnosticos seleccionados por dichos metodos
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
CA2417500A1 (en) Erbb-2 selective small molecule kinase inhibitors
IL171343A (en) Compound 1, 2, 4 - Oxadiazole Benzoic Acid, a pharmaceutical composition containing it, a method for testing the compound, and its use in the preparation of a drug for the treatment of early-onset disease before the end codon
BR0214805A (pt) Lama viscosa de alta perda de fluido solúvel em ácido para circulação perdida
BR0207332A (pt) Composição de fluido de fraturamento hidráulico, e, processo para gerar fissuras em uma formação subterrânea
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
AU2002255093A1 (en) Novel dyeing composition for dyeing keratinous fibres comprising a particular dicationic diazo dye
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
BRPI0415760A (pt) derivados de benzimidazolila
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
BR0114199A (pt) Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas
BRPI0416156A (pt) uso de tienopirimidinas
BRPI0801078A2 (pt) processo para relaxar ou alisar os cabelos
BRPI0410149A (pt) métodos para determinar caracterìsticas de formação e para determinar compactação de formação
BRPI0417732A (pt) aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
BR0308055A (pt) Processo para a preparação de compostos de azo catiÈnicos
BR0303912A (pt) Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
EP1572225A4 (en) THROMBOSPONDIN FRAGMENTS AND THEIR USE IN CLINICAL CANCER TESTS AND THE PRODUCTION OF ANTIBODIES AND OTHER BINDING AGENTS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2042 DE 23/02/2010.